Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.

Phillip J Mease Atul A Deodhar Désirée Mfm van der HeijdeFrank BehrensAlan J KivitzJeffrey NealJonghyeon KimShalabh SinghalMiroslawa NowakSubhashis Banerjee

Published in: Annals of the rheumatic diseases (2022)

NCT03881059.

Keyphrases

open label

randomized controlled trial

placebo controlled

double blind